Caroline Barnes
Nurse Practitioner · la Salle, ILNPI 1518216779
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 13 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by AstraZeneca at 36.5% of the total. Reporting peaked in 2022 at $294 and has fallen 69.3% since, to $90 in 2025.
Across 13 payments — averaging $36.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$171
- Sanofi-aventis U.S. LLC$118
- Novo Nordisk$83
- Xeris Pharmaceuticals, Inc.$33
- Tandem Diabetes Care, Inc.$24
- Insulet Corporation$22
- plus $18 from 1 others
What the payments were for
- Food & beverage$469100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $171 |
| Sanofi-aventis U.S. LLC | 3 | $118 |
| Novo Nordisk | 2 | $83 |
| Xeris Pharmaceuticals, Inc. | 2 | $33 |
| Tandem Diabetes Care, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $22 |
| EMD Serono, Inc. | 1 | $18 |
How this compares
$469 in reported general payments places this provider in the 70th percentile of 4,869 nurse practitioner providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 41 | $538 |
| Potassium Chloride | 17 | $317 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $293 |
| Anastrozole | 19 | $270 |
| Prednisone | 24 | $129 |
| Dexamethasone | 15 | $106 |
| Ondansetron Hcl | 12 | $101 |
| Prochlorperazine Maleate | 13 | $94 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 11 | $59 |
Paid to pharmacies, not to this prescriber.
Other nurse practitioner in la Salle
- Deepa VallikatWest Dundee$332K
- Maria MalotoNaperville$135K
- Valerie LaroyOak Lawn$112K
- Jennifer LiebChampaign$109K
- Tanya MungerRockford$106K
- Erika VuckoChicago$76K
- Yvonna OldakerFlossmoor$74K
- Heather PiercePekin$72K
- Dara McKinleyEvanston$66K
- Kristine WarnesNaperville$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.